黄芪甲苷新型给药系统的研究进展  

Research progress on astragaloside IV-loaded novel drug delivery systems

作　　者：罗开沛 江英杰 徐梦涵 杨文博 杨露 LUO Kai-pei;JIANG Ying-jie;XU Meng-han;YANG Wen-bo;YANG Lu(State Key Laboratory of Southwestern Chinese Medicine Resources,School of Pharmacy,Chengdu University of Traditional Chinese Medicine,Chengdu 611137,China;School of Pharmacy,Chengdu University of Traditional Chinese Medicine,Chengdu 611137,China;Innovative Institute of Chinese Medicine and Pharmacy,Chengdu University of Traditional Chinese Medicine,Chengdu 611137,China)

机构地区：[1]成都中医药大学西南特色中药资源国家重点实验室,四川成都611137 [2]成都中医药大学药学院,四川成都611137 [3]成都中医药大学中医药创新研究院,四川成都611137

出　　处：《中草药》2023年第18期6118-6127,共10页Chinese Traditional and Herbal Drugs

基　　金：国家自然科学基金资助项目(82204633);国家自然科学基金资助项目(82304880);中国博士后科学基金资助项目(2021M700550);四川省科技计划项目(2022NSFSC0634);四川省科技计划项目(2023NSFSC1782);成都中医药大学“杏林学者”学科人才科研提升计划项目(BSH2021024)。

摘　　要：黄芪甲苷是“补气之圣药”黄芪Astragali Radix的活性成分之一,具有抗炎、抗纤维化、抗氧化应激、抗哮喘、抗糖尿病、抗肿瘤、调节免疫和保护心脏等多种药理作用。然而,黄芪甲苷水溶性差、生物利用度低及病灶组织靶向性不足,极大地限制了开发应用。相较于传统制剂,新型递药系统能延长药物循环时间、控制药物释放、增加药物在病变部位的富集量,进而提高生物利用度,改善靶向性,增强疗效。通过对黄芪甲苷新型给药系统(单一给药系统及复合给药系统)的研究进展进行综述,并阐述其对多种疾病的治疗作用,探讨递药系统目前存在的问题及可能的应对策略,为黄芪甲苷新型制剂的开发及临床应用提供思路。Astragaloside-Ⅳis one of the active ingredients extracted from Huangqi(Astragali Radix),which has a wide range of pharmacological effects including anti-inflammatory,anti-fibrosis,anti-oxidative stress,anti-asthma,anti-diabetes,antitumor,immune regulation,and heart protection.However,the poor water solubility,low bioavailability,and insufficient tissue targeting of astragaloside IV greatly limit its development and application.Compared to traditional formulations,the novel drug delivery systems can improve bioavailability and targeting ability through prolonging circulation time,triggering drug release,increasing drug accumulation in deseased region,enhancing therapeutic efficacy.This paper summarized the research progress of astragaloside IV-loaded novel delivery systems(single and composite delivery systems),and elaborated on their therapeutic effects on various diseases.The current research problems and possible strategies of delivery systems were discussed,providing an idea for the development and clinical application of novel astragaloside IV formulations.

关 键 词：黄芪甲苷 新型给药系统 生物利用度 溶出度 治疗效果 临床转化 

分 类 号：R283[医药卫生—中药学]